Compare
Profound Medical Corp. vs Allurion Technologies, Inc. vs Vivos Therapeutics, Inc. vs Nephros Inc
| Latest fiscal year | Profound Medical Corp. PROF | Allurion Technologies, Inc. ALUR | Vivos Therapeutics, Inc. VVOS | Nephros Inc NEPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $16.10M | $15.23M | $17.44M | $18.79M |
| Revenue growth (YoY) | +50.7% | -52.6% | +16.0% | +32.7% |
| Gross margin | 70.8% | 62.8% | 60.4% | 61.9% |
| Operating margin | -256.3% | -198.0% | -114.1% | 6.1% |
| Net margin | -264.4% | -188.8% | -121.4% | 6.4% |
| Net income | -$42.57M | -$28.75M | -$21.17M | $1.19M |
| EPS (Diluted) | $1.41 | -$3.81 | -$2.07 | $0.11 |
| Operating cash flow | -$38.21M | -$28.95M | -$15.26M | $1.60M |
| Free cash flow | -$38.38M | n/a | -$17.60M | n/a |
| Cash & equivalents | $59.72M | $5.41M | $2.03M | $5.40M |
| Total assets | $77.47M | $15.77M | $25.15M | $13.64M |
| Total liabilities | $11.04M | $92.96M | $26.70M | $3.44M |
| Shareholders' equity | $66.43M | -$77.19M | -$1.49M | $10.20M |
| Return on year-end equity | -64.1% | n/a | n/a | 11.7% |
| Shares outstanding | 36.29M | 12.28M | 9.29M | 10.64M |
Revenue, most recent five fiscal years
| Fiscal year | Profound Medical Corp. | Allurion Technologies, Inc. | Vivos Therapeutics, Inc. | Nephros Inc |
|---|---|---|---|---|
| Latest | $16.10M Ended 2025-12-31 | $15.23M Ended 2025-12-31 | $17.44M Ended 2025-12-31 | $18.79M Ended 2025-12-31 |
| 1 year earlier | $10.68M Ended 2024-12-31 | $32.11M Ended 2024-12-31 | $15.03M Ended 2024-12-31 | $14.16M Ended 2024-12-31 |
| 2 years earlier | $7.20M Ended 2023-12-31 | $53.47M Ended 2023-12-31 | $13.80M Ended 2023-12-31 | $14.24M Ended 2023-12-31 |
| 3 years earlier | n/a | $64.21M Ended 2022-12-31 | $16.02M Ended 2022-12-31 | $9.97M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $16.89M Ended 2021-12-31 | $10.22M Ended 2021-12-31 |